newswire, breaking biotechnology and pharma news

Wednesday, November 3, 2010

NASDAQ Biotech/Pharma Market Leaders; (NASDAQ:BPAX), (NASDAQ:AMGN), (NASDAQ:LIFE) Stocks to Follow for Wednesday

Visit this company:
Point Roberts, WA - November 3, 2010 ( Newswire and -, a leader in sector research tools for investors, features a Biotech /Pharma Sector Snapshot featuring some of the NASDAQ�s Actively traded market leaders for today.

Biotech /Pharma Sector Trading Snapshot: (as of time of release November 3rd)

  • BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) trading at $1.52, up 0.02 (1.33%)
  • Amgen Inc. (NASDAQ:AMGN), trading at $57.40, up .04 (0.07%)
  • Life Technologies Corporation (NASDAQ:LIFE) trading at $ 50.71, up 0.22 (0.44%)
Market Summary:
  • Dow 11,211.88 +23.16 +0.21%
  • NASDAQ 2,534.96 +1.44 +0.06%
  • S&P 500 1,195.23 +1.66 +0.14%
  • 10 Yr Bond (%) 2.5490% -0.0450
  • Oil 84.42 +0.52 +0.62%
  • Gold 1,353.00 -3.40 -0.25%
Biotech/Pharma Stocks Recent News;
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Reports Positive LibiGel� Data Monitoring Committee Recommendation
No safety issues observed, study to continue as per protocol without modifications
LINCOLNSHIRE, Ill. - ( newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the Phase III LibiGel (testosterone gel) cardiovascular and breast cancer safety study will continue without modifications and will continue to enroll new subjects as a result of the fourth unblinded review of adverse events and the first unblinded statistical analysis for sample-size determination by its independent Data Monitoring Committee (DMC). The review and statistical analysis were based on 2,500 subjects who have been enrolled in the study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is currently no FDA approved product.
Full news:
More news - Visit the BPAX showcase profile at

Disclosure, Disclaimer/ BPAX is a paid advertising client on
Life Technologies Corporation (NASDAQ:LIFE) News:
Life Technologies Launches New SOLiD Sequencer to Drive Advances in Cancer Biology and Genetic Disease Research
"Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD™ Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.
Developed and manufactured with long-standing partner Hitachi High-Technologies, the 5500xl delivers on the promise of the SOLiD 4hq, which was first announced in January. Initial shipments of the 5500xl are planned for December 2010."
Full Article:
About Life Technologies Corporation (NASDAQ:LIFE)
Life Technologies Corporation (NASDAQ:LIFE - News) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:
Research other biotech stocks at the Biotech stocks Directory:
More info on BPAX:
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Investor Fact Sheet update and News:

Full Media Kit at:
Financial Highlights
  • At September 30, 2010, BioSante had approximately $36M in cash
  • Monthly burn rate of approximately $3.5M
Investment Highlights
  • Financial resources to implement plan
  • Late stage pharmaceutical product portfolio with significant growth potential
  • LibiGel in three ongoing Phase III safety and efficacy clinical studies
  • Elestrin is FDA approved and marketed in the U.S.
  • Proprietary cancer vaccines in Phase II clinical trials
  • Focused growth strategy
  • Management's proven ability to gain FDA approval, implement plans and increase stockholder value
About is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.
Sign up for free stock alerts on biotech stocks and other leading sectors!
About our Biotech investor portal: is a global meeting place for investors and industry following the biotech and pharma sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Disclaimer/disclosure : The following news is sponsored for by showcase stocks BPAX (three thousand per month BPAX) is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal. This site is currently compensated by featured companies, news submissions and online advertising.
More info: Disclaimer: Disclosure:
C Van Zant: 800-665-0411 -
Source -
More Info:
Published at - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

No comments:

Post a Comment